|
| 36882456 | Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes. | Sci Rep | 2023 |
| 37726477 | Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives. | Br J Cancer | 2023 |
| 37013636 | A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer. | Genome Med | 2023 |
| 36882456 | Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes. | Sci Rep | 2023 |
| 37382186 | Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial. | Cancer | 2023 |
| 37253493 | Protocol for a comprehensive prospective cohort study of trio-based whole-genome sequencing for underlying cancer predisposition in paediatric and adolescent patients newly diagnosed with cancer: the PREDICT study. | BMJ Open | 2023 |
| 37001527 | Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. | Cancer Cell | 2023 |
| 37523146 | High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer. | Cancer Res | 2023 |
| 37511646 | Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial. | J Pers Med | 2023 |
| 37523146 | High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer. | Cancer Res | 2023 |
| 37511646 | Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial. | J Pers Med | 2023 |
| 37726477 | Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives. | Br J Cancer | 2023 |
| 37253493 | Protocol for a comprehensive prospective cohort study of trio-based whole-genome sequencing for underlying cancer predisposition in paediatric and adolescent patients newly diagnosed with cancer: the PREDICT study. | BMJ Open | 2023 |
| 37382186 | Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial. | Cancer | 2023 |
| 37013636 | A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer. | Genome Med | 2023 |
| 37001527 | Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. | Cancer Cell | 2023 |
| 34471258 | Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. | Br J Cancer | 2022 |
| 35643837 | Returning raw genomic data: rights of research participants and obligations of health care professionals. | Med J Aust | 2022 |
| 36066496 | The Voices of Stakeholders Involved in Precision Medicine: The Co-Design and Evaluation of Qualitative Indicators of Intervention Acceptability, Fidelity and Context in PRecISion Medicine for Children With Cancer in Australia. | Qual Health Res | 2022 |
| 34471258 | Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. | Br J Cancer | 2022 |
| 35643837 | Returning raw genomic data: rights of research participants and obligations of health care professionals. | Med J Aust | 2022 |
| 36066496 | The Voices of Stakeholders Involved in Precision Medicine: The Co-Design and Evaluation of Qualitative Indicators of Intervention Acceptability, Fidelity and Context in PRecISion Medicine for Children With Cancer in Australia. | Qual Health Res | 2022 |
| 33580196 | Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor. | NPJ Precis Oncol | 2021 |
| 33580196 | Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor. | NPJ Precis Oncol | 2021 |
| 32438909 | The rise of rapid implementation: a worked example of solving an existing problem with a new method by combining concept analysis with a systematic integrative review. | BMC Health Serv Res | 2020 |
| 32075154 | "Balancing Expectations with Actual Realities": Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial. | J Pers Med | 2020 |
| 31876116 | Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. | Pediatr Blood Cancer | 2020 |
| 32438909 | The rise of rapid implementation: a worked example of solving an existing problem with a new method by combining concept analysis with a systematic integrative review. | BMC Health Serv Res | 2020 |
| 32580982 | Development of an implementation and evaluation strategy for the Australian 'Zero Childhood Cancer' (Zero) Program: a study protocol. | BMJ Open | 2020 |
| 31876116 | Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. | Pediatr Blood Cancer | 2020 |
| 32075154 | "Balancing Expectations with Actual Realities": Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial. | J Pers Med | 2020 |
| 32580982 | Development of an implementation and evaluation strategy for the Australian 'Zero Childhood Cancer' (Zero) Program: a study protocol. | BMJ Open | 2020 |
| 31693904 | Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. | Cell Rep | 2019 |
| 31693904 | Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. | Cell Rep | 2019 |
| 30299205 | Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. | Cancer Biol Ther | 2018 |
| 30220707 | Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. | Br J Cancer | 2018 |
| 30299205 | Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. | Cancer Biol Ther | 2018 |
| 30220707 | Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. | Br J Cancer | 2018 |
| 27294016 | Quality standards for DNA sequence variation databases to improve clinical management under development in Australia. | Appl Transl Genom | 2014 |
| 27294016 | Quality standards for DNA sequence variation databases to improve clinical management under development in Australia. | Appl Transl Genom | 2014 |